Neuphoria Therapeutics Stock Price Patterns
| NEUP Stock | 4.05 0.05 1.25% |
Momentum 46
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (1.31) | EPS Estimate Current Year (4.07) | EPS Estimate Next Year (3.85) | Wall Street Target Price 9.7667 |
Using Neuphoria Therapeutics hype-based prediction, you can estimate the value of Neuphoria Therapeutics from the perspective of Neuphoria Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Neuphoria Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Neuphoria because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Neuphoria Therapeutics after-hype prediction price | USD 3.99 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Neuphoria | Build AI portfolio with Neuphoria Stock |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuphoria Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuphoria Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Neuphoria Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neuphoria Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Neuphoria Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Neuphoria Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Neuphoria Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neuphoria Therapeutics' historical news coverage. Neuphoria Therapeutics' after-hype downside and upside margins for the prediction period are 1.12 and 6.86, respectively. We have considered Neuphoria Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Neuphoria Therapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of Neuphoria Therapeutics is based on 3 months time horizon.
Neuphoria Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Neuphoria Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuphoria Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neuphoria Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.25 | 2.87 | 0.00 | 0.01 | 7 Events / Month | 6 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
4.05 | 3.99 | 0.25 |
|
Neuphoria Therapeutics Hype Timeline
Neuphoria Therapeutics is now traded for 4.05. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Neuphoria is anticipated to decline in value after the next headline, with the price expected to drop to 3.99. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.25%, whereas the daily expected return is now at -0.25%. The volatility of related hype on Neuphoria Therapeutics is about 13666.67%, with the expected price after the next announcement by competition of 4.04. About 46.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neuphoria Therapeutics recorded a loss per share of 4.02. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 24th of December 2024. Given the investment horizon of 90 days the next anticipated press release will be in about 7 days. Check out Neuphoria Therapeutics Basic Forecasting Models to cross-verify your projections.Neuphoria Therapeutics Related Hype Analysis
Having access to credible news sources related to Neuphoria Therapeutics' direct competition is more important than ever and may enhance your ability to predict Neuphoria Therapeutics' future price movements. Getting to know how Neuphoria Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neuphoria Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PTHL | Pheton Holdings Ltd | 0.05 | 6 per month | 6.77 | 0.02 | 6.56 | (9.84) | 136.77 | |
| IINN | Inspira Technologies Oxy | 0.07 | 9 per month | 0.00 | (0.11) | 7.29 | (7.14) | 24.08 | |
| BMRA | Biomerica | (0.05) | 7 per month | 0.00 | (0.06) | 4.37 | (4.98) | 18.44 | |
| PFSA | Profusa Common Stock | (0.06) | 7 per month | 0.00 | (0.11) | 11.82 | (20.30) | 115.38 | |
| APRE | Aprea Therapeutics | 0.02 | 7 per month | 0.00 | (0.14) | 4.44 | (10.58) | 46.26 | |
| CHEK | Check Cap | 0.01 | 8 per month | 6.07 | 0.12 | 17.16 | (10.37) | 198.26 | |
| LUCY | Innovative Eyewear | 0.01 | 8 per month | 0.00 | (0.03) | 14.00 | (9.83) | 57.39 | |
| BCDA | Biocardia | 0.01 | 8 per month | 0.00 | (0.03) | 5.93 | (6.03) | 17.38 | |
| ALZN | Alzamend Neuro | (0.27) | 8 per month | 0.00 | (0.11) | 6.12 | (6.17) | 19.96 | |
| LFWD | ReWalk Robotics | 0.00 | 5 per month | 4.16 | 0.01 | 10.14 | (6.58) | 34.28 |
Neuphoria Therapeutics Additional Predictive Modules
Most predictive techniques to examine Neuphoria price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neuphoria using various technical indicators. When you analyze Neuphoria charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Neuphoria Therapeutics Predictive Indicators
The successful prediction of Neuphoria Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Neuphoria Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Neuphoria Therapeutics based on analysis of Neuphoria Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Neuphoria Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neuphoria Therapeutics's related companies. | 2025 | 2026 (projected) | Payables Turnover | 0.001011 | 9.6E-4 | Days Of Inventory On Hand | 21.38 | 23.55 |
Pair Trading with Neuphoria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neuphoria Stock
Moving against Neuphoria Stock
| 0.73 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.59 | DSGN | Design Therapeutics | PairCorr |
| 0.5 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.43 | ENGN | enGene Holdings Common | PairCorr |
| 0.34 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Neuphoria Stock Analysis
When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.